| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LILRA5 |
| Uniprot No | A6NI73-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-268aa |
| 氨基酸序列 | MAPWSHPSAQ LQPVGGDAVS PALMVLLCLG LSLGPRTHVQ AGNLSKATLW AEPGSVISRG NSVTIRCQGT LEAQEYRLVK EGSPEPWDTQ NPLEPKNKAR FSIPSMTEHH AGRYRCYYYS PAGWSEPSDP LELVVTGFYN KPTLSALPSP VVTSGENVTL QCGSRLRFDR FILTEEGDHK LSWTLDSQLT PSGQFQALFP VGPVTPSHRW MLRCYGSRRH ILQVWSEPSD LLEIPVSGAA DNLSPSQNKS DSGTASHLQD YAVENLIR |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LILRA5重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: *LILRA5 modulates inflammatory responses in human macrophages through interaction with MHC class I molecules*
**作者**: Chen Y, et al.
**摘要**: 该研究通过表达LILRA5重组蛋白，发现其与MHC I类分子结合后可激活巨噬细胞炎症信号通路(如NF-κB)，促进促炎因子(如TNF-α、IL-6)释放，提示其在自身免疫疾病中的潜在作用。
2. **文献名称**: *Structural and functional characterization of recombinant LILRA5 reveals its role in regulating dendritic cell maturation*
**作者**: Smith J, et al.
**摘要**: 通过晶体学解析LILRA5重组蛋白结构，发现其免疫球蛋白样结构域与配体结合后调控树突状细胞成熟，抑制TLR信号通路，可能参与免疫耐受机制。
3. **文献名称**: *LILRA5 acts as a viral RNA sensor to exacerbate antiviral responses in systemic lupus erythematosus*
**作者**: Wang L, et al.
**摘要**: 研究发现重组LILRA5蛋白可结合病毒RNA(如dsRNA)，增强I型干扰素产生，并在系统性红斑狼疮患者外周血单核细胞中异常高表达，提示其与疾病活动性相关。
注：以上文献为示例，实际引用需根据具体研究内容检索PubMed或Google Scholar获取原文信息。
**Background of LILRA5 Recombinant Protein**
Leukocyte immunoglobulin-like receptor A5 (LILRA5), also known as CD85h or LILRB7. is a member of the LILR family, a group of immunomodulatory receptors expressed primarily on immune cells such as monocytes, macrophages, and dendritic cells. Structurally, LILRA5 is a transmembrane glycoprotein containing extracellular immunoglobulin-like domains, typical of the immunoglobulin superfamily (IgSF). Unlike other LILRs that often exhibit inhibitory or activating functions through intracellular signaling motifs, LILRA5 is classified as a "pseudoreceptor" due to its truncated cytoplasmic tail, which lacks canonical signaling domains. This unique feature suggests it may regulate immune responses through alternative mechanisms, such as ligand sequestration or crosstalk with other receptors.
LILRA5 binds to MHC class I molecules and other ligands, potentially modulating innate immune activation, antigen presentation, or inflammatory responses. Its role in disease contexts, including autoimmune disorders, infections, and cancer, has garnered interest. For instance, aberrant LILRA5 expression has been linked to rheumatoid arthritis and lupus, where dysregulated immune signaling contributes to pathogenesis.
Recombinant LILRA5 protein is produced via heterologous expression systems (e.g., mammalian or insect cells) to ensure proper post-translational modifications. This engineered protein retains the functional extracellular domain, enabling studies on ligand-receptor interactions, signaling pathways, and therapeutic targeting. Researchers utilize it to investigate LILRA5's biological functions, develop blocking antibodies, or explore its potential as a biomarker. Additionally, it serves as a tool for structural studies (e.g., crystallography) to elucidate binding interfaces and mechanistic insights.
Overall, LILRA5 recombinant protein is a critical reagent for dissecting the complex roles of LILRs in immune regulation and disease, offering avenues for novel therapeutic strategies.
×
